AR and prostate carcinoma: Low B55γ expression has been documented to promote prostate cancer growth independent of androgen receptor–mediated transcriptional programs, is found in primary and metastatic prostate cancer tumors, and is associated with poor disease outcome, suggesting that it plays a critical role in prostate cancer progression (106).